Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MMP3 | P08254 | 18/20 | 0.57 |
| ▸ | MMP1 | P03956 | 17/20 | 0.57 |
| ▸ | MMP9 | P14780 | 14/20 | 0.57 |
| ▸ | MMP7 | P09237 | 9/20 | 0.57 |
| ▸ | ADAM17 | P78536 | 5/20 | 0.57 |
| ▸ | MMP2 | P08253 | 3/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 7/20 | 0.55 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4034013 | 1.00 | ALDH1A1 (0.58) | ALDH1A1MMP3MMP1MMP9MMP7 | |
| SCHEMBL4028682 | 0.96 | ALDH1A1 (0.55) | ALDH1A1MMP3MMP1MMP9MMP7 | |
| SCHEMBL6491614 | 0.93 | ALDH1A1 (0.61) | ALDH1A1MMP3MMP1MMP9MMP7 | |
| SCHEMBL14575007 | 0.93 | ALDH1A1 (0.61) | ALDH1A1MMP3MMP1MMP9MMP7 | |
| SCHEMBL6493434 | 0.93 | ALDH1A1 (0.61) | ALDH1A1MMP3MMP1MMP9MMP7 | |
| SCHEMBL4032000 | 0.93 | ALDH1A1 (0.61) | ALDH1A1MMP3MMP1MMP9MMP7 | |
| SCHEMBL4025866 | 0.86 | ALDH1A1 (0.55) | ALDH1A1PKM | |
| SCHEMBL1770573 | 0.80 | HDAC3 (0.50) | ALDH1A1PKM | |
| SCHEMBL1770667 | 0.80 | HDAC3 (0.50) | ALDH1A1PKM | |
| SCHEMBL6480554 | 0.79 | ALDH1A1 (0.59) | ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1452527-B1 | AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION | SHISEIDO CO LTD (JP) | 2009-03-04 | — | — | EP | disclosed |
| US-7176217-B2 | Azabicyclo compound matrix metalloprotease inhibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176217-B2 | Azabicyclo compound matrix metalloprotease inhibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-7176217-B2 | Azabicyclo compound matrix metalloprotease inhibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050009808-A1 | Azabicyclo compound matrix metalloprotease inibitor and skin preparation | SHISEIDO CO., LTD. (JP) | 2005-01-13 | — | — | US | disclosed |
| EP-1452527-A1 | AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION | Shiseido Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009808-A1 | Azabicyclo compound matrix metalloprotease inibitor and skin preparation | MMP1, MMP16, MMP9 | ALDH1A1 1160/4885MMP3 17/4885MMP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.